https://www.thebodypro.com/author/richard-jefferys

Latest by Richard Jefferys

Mosaic Antigens and Mountaineering Metaphors: Climbing Toward the Next HIV Vaccine Efficacy Trial Img
IAS (International AIDS Society) Conference

Mosaic Antigens and Mountaineering Metaphors: Climbing Toward the Next HIV Vaccine Efficacy Trial

Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.

HIV Remission News From IAS 2017 Img
IAS (International AIDS Society) Conference

HIV Remission News From IAS 2017

Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort Img

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort

Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART

"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.

Flagging the HIV Reservoir: A Potential New Marker for CD4 Cells Hiding HIV Img

Flagging the HIV Reservoir: A Potential New Marker for CD4 Cells Hiding HIV

New research shows that it may be possible to identify many latently infected CD4 T cells due to expression of a particular cell surface protein.

Capsules From CROI 2017 Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Capsules From CROI 2017

Richard Jefferys analyzes key presentations from this year's Conference on Retroviruses and Opportunistic Infections.

Targeting Latently Infected Cells via IFITM1 Img

Targeting Latently Infected Cells via IFITM1

HIV cure researchers seek out markers that would allow the specific targeting of cells harboring latent HIV. Enter a new candidate: interferon-induced transmembrane protein 1 (IFITM1).

Antibody Therapy Leads to Sustained Post-Treatment SIV Control in Macaques Img

Antibody Therapy Leads to Sustained Post-Treatment SIV Control in Macaques

"The results of the study appear very encouraging, and the researchers are hoping to rapidly evaluate whether they have any relevance to humans," Richard Jefferys writes. "A small clinical trial of the anti-α4β7 antibody vedolizumab, which is FDA-app...

Snipping the HIV Genome Out of Latently Infected Cells

Snipping the HIV Genome Out of Latently Infected Cells

One of the more futuristic-sounding ideas for curing HIV involves removing the genome of the virus from the genome of the cells into which it has integrated. On paper, the idea is very appealing, but there are a multitude of challenges.

New Data on the Latency-Reversing Activity of Disulfiram Img

New Data on the Latency-Reversing Activity of Disulfiram

The FDA-approved drug disulfiram (Antabuse) may be able to awaken hidden HIV -- in a small, but significant way -- according to results of a clinical trial in 30 HIV-positive individuals on antiretroviral therapy.